Director/PDMR Shareholding
November 1, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transactions by persons discharging managerial responsibilities
1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Flemming Ornskov | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Chief Executive Officer - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Automatic exercise of option over notional ADSs granted under the Shire Global Employee Stock Purchase Plan on November 1, 2017, and consequent receipt of ADSs. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 125.49 | 99 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | October 31, 2018 | ||
| f) | Place of the transaction | N/A | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Joanne Cordeiro | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Chief Human Resources Officer - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Automatic exercise of option over notional ADSs granted under the Shire Global Employee Stock Purchase Plan on November 1, 2017, and consequent receipt of ADSs. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 125.49 | 99 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | October 31, 2018 | ||
| f) | Place of the transaction | N/A | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Bill Mordan | ||
| 2. | Reason for the notification | |||
| a) | Position / status | General Counsel and Company Secretary - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Automatic exercise of option over notional ADSs granted under the Shire Global Employee Stock Purchase Plan on November 1, 2017, and consequent receipt of ADSs. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 125.49 | 99 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | October 31, 2018 | ||
| f) | Place of the transaction | N/A | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Perry Sternberg | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Head of US Commercial - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Automatic exercise of option over notional ADSs granted under the Shire Global Employee Stock Purchase Plan on November 1, 2017, and consequent receipt of ADSs. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 125.49 | 99 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | October 31, 2018 | ||
| f) | Place of the transaction | N/A | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Kim Stratton | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Head of International Commercial - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”) | ||
| Identification code | ISIN: JE00B2QKY057 | |||
| b) | Nature of the transaction | Automatic exercise of option over notional Ordinary Shares granted under the Shire Global Employee Stock Purchase Plan on November 1, 2017, and consequent receipt of Ordinary Shares. (Details of related disposal of Ordinary Shares are referenced in section 5. below.) | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| £ | 31.63 | 297 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | October 31, 2018 | ||
| f) | Place of the transaction | N/A | ||
| 5. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”) | ||
| Identification code | ISIN: JE00B2QKY057 | |||
| b) | Nature of the transaction | Automatic disposal of Ordinary Shares related to the automatic option exercise referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the option exercise. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| £ | 46.5224 | 29 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | October 31, 2018 | ||
| f) | Place of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Matt Walker | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Head of Technical Operations - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Automatic exercise of option over notional ADSs granted under the Shire Global Employee Stock Purchase Plan on November 1, 2017, and consequent receipt of ADSs. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 125.49 | 99 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | October 31, 2018 | ||
| f) | Place of the transaction | N/A | ||
Sarah Rixon
Senior Company Secretarial Assistant
For further information please contact:
| Investor Relations | ||
| Christoph Brackmann | christoph.brackmann@shire.com | +41 41 288 41 29 |
| Sun Kim | sun.kim@shire.com | +1 617 588 8175 |
| Scott Burrows | scott.burrows@shire.com | +41 41 288 4195 |
| Media | ||
| Katie Joyce | kjoyceshire.com | +1 781 482 2779 |
NOTES TO EDITORS
About Shire
Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.
Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.